Long-term hearing results and otological complications of nasopharyngeal carcinoma patients: comparison between treatment with conventional two-dimensional radiotherapy and intensity-modulated radiotherapy by Ho, WK et al.
Title
Long-term hearing results and otological complications of
nasopharyngeal carcinoma patients: comparison between
treatment with conventional two-dimensional radiotherapy and
intensity-modulated radiotherapy
Author(s) Tsang, RK; Kwong, DL; Ho, AC; To, VS; Ho, WK; Wei, WI
Citation ORL: Journal for Oto-rhino-laryngology and Its RelatedSpecialties, 2012, v. 74 n. 4, p. 228-233
Issued Date 2012
URL http://hdl.handle.net/10722/163919
Rights ORL: Journal for Oto-rhino-laryngology and Its RelatedSpecialties. Copyright © S. Karger AG.
 1 
Long term hearing results and otological complications of 
nasopharyngeal carcinoma patients: Comparison between 
treatment with conventional two-dimensional radiotherapy 
and intensity-modulated radiotherapy 
Raymond K. TSANG FRCSE1 
Dora L. KWONG FRCR2 
Ambrose C. HO FRCSE1 
Victor S. TO FRCSE1 
Wai-Kuen HO FRCSE1 
William I. WEI FRCS, FRCSE1 
 
Division of Otorhinolaryngology – Head and Neck Surgery, Department of Surgery1 
and Department of Clinical Oncology2, University of Hong Kong, Hong Kong SAR, 
China. 
 
Short title: Audiological and otological complications after RT for NPC 
Correspondence: 
Dr. Raymond K. Tsang 
Department of Surgery, University of Hong Kong 
Queen Mary Hospital, 102 Pokfulam Road, 
Hong Kong SAR. 
E-mail: rkytsang@hku.hk 
Fax: (852) 2819 3780 
Tel: (852) 2255 4394 
The authors have no funding, financial relationships, or conflicts of interest to 
disclose.
 2 
Abstract 
Objective: To assess the long-term audiological outcome and otological complications 
of nasopharyngeal carcinoma (NPC) patients who have received intensity-modulated 
radiotherapy (IMRT) versus conventional two-dimension radiotherapy (2DRT). 
Study Design: Prospective study on the audiological outcome and otological 
complications 5-9 years after radiotherapy.  
Methodology:  Patients had pure tone audiogram before radiotherapy and 5 years after 
radiotherapy.  Otological examination was performed 5 to 9 years after radiotherapy 
by otolaryngologist. 
Results: There is significant deterioration of hearing threshold 5 years after 
radiotherapy but there is no statistical significant difference in the deterioration of 
hearing between IMRT and 2DRT.  6 patients in the 2DRT group and 1 patient in 
IMRT group had osteoradionecrosis of the external auditory canal (p=0.042).  
Conclusion:  There are fewer incidences of osteoradionecrosis of external auditory 
canal in patients treated with IMRT.   There is no difference in bone conduction 
threshold in patients treated with IMRT or 2DRT.   
 
Keywords: Nasopharyngeal carcinoma; intensity-modulated radiotherapy; 
sensorineural hearing loss; osteoradionecrosis. 
 3 
Introduction 
 
 Nasopharyngeal carcinoma (NPC) is the commonest head and neck cancer in 
Southern China; it is the fifth commonest cancer in male in Hong Kong.  
Radiotherapy is the primary treatment modality of nasopharyngeal carcinoma.  The 
technique of intensity-modulated radiotherapy (IMRT) further enhances the efficacy 
of radiotherapy for NPC and studies have shown that IMRT alone offers excellent 
locoregional control in early stage NPC[1-3].  When comparing with conventional 
two-dimensional radiotherapy (2DRT), there is less radiation to the adjacent 
structures like parotid glands and temporomandibular joints when IMRT is employed 
for treatment of early NPC[4].  Studies have shown that IMRT improves the quality 
of life of NPC patient after radiotherapy when compared to conventional 2D 
radiotherapy, especially in regard to preservation of salivary function[1, 5].  Radiation 
can damage the inner ear structures and neural pathways leading to hearing loss[6, 7].  
Long term follow up studies have shown that NPC patients suffered from significant 
sensorineural hearing loss after radiotherapy treatment[8, 9].  The unique advantage 
of IMRT in offering adequate radiation dosage to the tumor while reducing the 
radiation dosage to the surrounding normal tissue may reduce the long term 
sensorineural hearing loss in NPC patients treated with radiotherapy.  In this study we 
would like to compare the long term hearing results and otological complications in 
two groups of patients; one group treated with conventional 2DRT and the other 
group treated with IMRT.   In order to avoid the confounding factor of ototoxicity 
from chemotherapy, no patients in the cohort received chemotherapy. 
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Materials and Methods 
 
Patients 
 From January 2001 to March 2005, patients with UICC 2002 stage II 
nasopharyngeal carcinoma (T1N1, T2N0, T2N1 disease) were treated with 
radiotherapy alone with either 2DRT or IMRT. As IMRT was a novel treatment at 
that time, 2DRT was the standard of care. The choice of RT was based either in a trial 
setting or according to patient’s preference or physician’s decision. The pretreatment 
evaluation included a complete history and physical examination, nasopharyngoscopy, 
chest X-ray, complete blood count, liver and renal biochemistry.  Patients were stage 
with contrast computer tomography (CT) scans to determine the eligibility to enter the 
study.  None of the patients received neoadjuvant, concurrent or adjuvant 
chemotherapy, as our institution treatment protocol did not employ chemotherapy for 
stage II disease. 
2DRT 
 2DRT were performed in 2 sequential phases. Phase I started with 2 large 
lateral opposing facio-cervical fields covering the nasopharynx and upper cervical 
lymph nodes and any parapharyngeal extension. 40Gy was given in 2Gy/fraction, 5 
fractions per week in 4 weeks. After 40Gy, phase II treatment continued with 1 
anterior facial and 2 lateral opposing fields to the nasopharynx to avoid the spinal 
cord to another 28Gy in same fractionation. The total dose to nasopharynx was 68Gy 
in 34 fractions. As the temporal bones were irradiated in both lateral fields during 
both phase I and phase II 2DRT, the dose to temporal bone is considered the same as 
the dose to nasopharynx, that is, about 68Gy. The lower neck was treated with a 
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separate anterior cervical field with midline shield to protect the spinal cord. The dose 
to the neck was 66Gy in 33 fractions. 
IMRT 
 The nasopharynx and upper neck was treated with IMRT. IMRT was 
performed with Corvus system (MIMiC from NOMOS, Sewickley, USA). Treatment 
targets and organ at risks were localized on planning CT scan with patient in 
immobilization cast. The gross tumor volume included the tumor in nasopharynx and 
any tumor extension outside nasopharynx identified clinically or radiologically. The 
clinical target volume covered the gross tumor volume with margins to include any 
potential microscopic disease extension. The clinical target volume typically extended 
from the skull base to level II, III nodal regions on both sides. The planning target 
volume was clinical target volume with additional 3mm margin to account for 
potential set-up error in treatment. The dose to planning target volume to nasopharynx 
was 68-70Gy in 34 fractions, 5 daily fractions per week. The lower neck was treated 
with a matching anterior cervical field with midline shield to 66Gy in 33 fractions. 
The inner, middle and external ears on both sides were localized as organs at risk in 
IMRT planning and the doses to these structures were limited at 50Gy. 
 
Audiological and otological assessments 
 All patients underwent otoscopic assessment by an otolaryngologist and pure 
tone audiogram (PTA) by an audiologist before the start of radiotherapy.  Patients 
with otitis media with effusion were offered myringotomy and grommet insertion.  A 
repeat PTA would be obtained if patient underwent grommet insertion and the post-
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operative audiogram would be used for baseline assessment.  The PTA included air 
conduction (AC) at frequency 256Hz, 512Hz, 1kHz, 4kHz and 8kHz and bone 
conduction (BC) at frequency 512Hz, 1kHz, 2kHz and 4kHz.  Masking thresholds 
were obtained whenever it was appropriate.  Patients had an audiogram performed 5 
years after radiotherapy.  As air conduction thresholds could be affected by middle 
ear pathologies, to measure the effect of radiation damage to inner ear, the bone 
conduction thresholds were used for statistical calculations.  Similar to previous study 
by Ho, we calculated the pure tone average (PTAv), the average of thresholds at 
512Hz, 1kHz, and 2kHz to reflect the threshold in speech range. The bone conduction 
threshold at 4kHz was chosen to represent high frequency threshold.  Since the 
maximal output of the bone conductor of the audiometer is 65dB, it would not be 
possible to accurately measure the true threshold if the BC threshold was worse than 
65dB.  For ears with BC threshold worse than 65dB and no clinical or 
tympanometrical evidence of conductive hearing loss, the BC threshold would be 
assumed equivalent to the AC threshold. 
Patients had otoscopic or microscopic examination of the ears by 
otolaryngologists in year 2010, 5 to 9 years after completion of radiotherapy.  The 
presence of OME, eardrum perforation, grommet and osteoradionecrosis (ORN) of 
the external auditory canal were noted.  Presence of exposed bone with bony 
sequestrum in the external auditory canal was use as the diagnostic hallmark of ORN 
of the external auditory canal[10].  Otitis media with effusion was confirmed with the 
presence of type B curve on tympanometry.   
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Statistical calculations 
Individual ear would be used for statistical calculations.  The serial change in 
hearing of individual ear after radiotherapy was determined by the paired t-test.  For 
comparison between the changes in hearing of patients who received 2DRT versus 
IMRT, the change in the hearing threshold was calculated and the significance 
determined by t-test.  Chi-square test and Fisher exact test were used for comparison 
of the occurrence of ORN, presence of grommets, OME and perforations between the 
two groups.  A two tailed p value of less then 0.05 was considered significant.  All 
statistical tests were calculated with SPSS 18.0 (Chicago, IL). 
 
Results 
 
 Eighty-two patients (63 male and 19 female), 164 ears were recruited into the 
study, with each ear considered as an independent case. The age of patients ranged 
from 27 to 75 years old, with a median age of 46 years. There are 40 patients in the 
conventional 2DRT group and 42 patients in the IMRT group.  There was no 
difference in the age, sex distribution and pre-treatment audiological threshold 
between the two groups of patients.  The summary of the demographic data was 
shown in table 1.   Eleven patients died within 5 years of completion of radiotherapy.  
Four patients developed local recurrence in the nasopharynx and were all salvaged 
with nasopharyngectomy via maxillary swing, the four patients are excluded from the 
study.  One patient developed recurrence in the right parotid region and received a 
second dose of radiotherapy.  One patient developed disseminated disease and 
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received cisplatin chemotherapy.  Both patients were excluded from the study.  
Twelve patients were lost to follow up. 
 
Audiological results 
Complete audiological information at 5 years post-irradiation was available in 
106 ears. 56 ears and 50 ears received IMRT and conventional radiotherapy 
respectively.  There was no statistical difference in the age of the two groups of 
patients (p=0.38, t-test).  Pre-irradiation hearing level and audiological information at 
5-year follow-up was analysed.  For the PTAv, the overall mean pre-irradiation BC 
level was 17.9dB (SD = 9.2dB) and the mean level at 5 year follow-up was 24.6 dB 
(SD = 16.6dB). Comparing with pre-irradiation hearing threshold, there was an 
average deterioration of hearing of 6.6dB (95% CI 4.4dB - 8.9dB) at 5 years after 
radiotherapy, which was statistically significant (paired t-test, p<0.001). At 4kHz, the 
overall mean pre-irradiation BC level was 26.4dB (SD = 17.1dB) and the mean BC 
level at 5 year follow-up was 41.4dB (SD = 26.0dB). The mean deterioration of 
hearing at 4kHz was 15.0dB (95% CI 2.0dB – 21.1dB), which was again significant 
(paired t-test, p<0.001).  Table 2 shows the bone conduction thresholds of the whole 
cohort before and after radiotherapy. 
 The average deterioration in PTAv in the 2DRT group and IMRT group are 
7.0dB and 6.2dB respectively, and this is not statistically significant (p=0.74, t-test).  
The average deterioration in hearing at 4kHz in the 2DRT and IMRT group are 
13.8dB and 16.2dB respectively and this is statistically not significant (p=0.57, t-test).  
Table 3 summarized the hearing results of the two groups of patients.  The average 
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difference in the change in hearing between the two groups of patients is less than 
5dB and clinically this small difference is not significant.   
 
Otological complications 
 Ninety-four ears (47 patients), 52 ears in the IMRT group and 42 ears in the 
2DRT group were available for otological assessment.  In the IMRT group, 1 out of 
52 ears (1.9%) had osteoradionecrosis while in the conventional radiotherapy group, 6 
in 42 ears (14.3%) had osteoradionecrosis.  The difference in the occurrence of 
osteoradionecrosis between the two groups was significant. (Fisher’s exact test, p = 
0.042).  Otitis media with effusion was present in 14 ears (26.9%) in the IMRT group 
and 3 ears (7.1%) in the conventional radiotherapy group.  The difference between the 
two groups was significant (p=0.016, Fisher’s exact test).  One ear in the IMRT group 
had a grommet present and one ear in the 2DRT group had a grommet present during 
otological assessment.  One ear in the IMRT had a chronic perforation of the 
tympanic membrane and one ear in the 2DRT group had a chronic perforation of the 
tympanic membrane.  Table 4 summarized the otological findings.   
 In summary, from our present cohort, there is statistical significant 
deterioration in the bone conduction threshold in the speech frequency and in the high 
tone in the whole cohort five years after radiotherapy treatment for NPC.  We are 
unable to demonstrate any difference in the deterioration of bone conduction 
threshold between patients treated with IMRT or 2DRT.  Patients who received 2DRT 
have a higher incidence of developing osteoradionecrosis of the external auditory 
canal comparing with patients who received IMRT.  On the contrary, patients who 
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received IMRT have a higher incidence of otitis media with effusion than patients 
who received 2DRT. 
 
Discussion 
 Radiation therapy has been known to damage the auditory apparatus and 
hearing.  Previous study in our institute has demonstrated the presence of long term 
hearing loss after radiotherapy for nasopharyngeal carcinoma[8].  The presence study 
confirmed this finding.  The deterioration in hearing could not be attributed to aging 
alone.  Robinson and Sutton had calculated that the expected age-related threshold 
shift in 5 years should be in the range of 2.6 to 4.6 dB for 4kHz and 1.3 to 1.4dB for 
PTAv.  The present study showed that the average change in hearing thresholds 5 
years after radiotherapy are 15.2dB at 4kHz and 7.3dB for PTAv.   The present study 
also demonstrated that there is more significant damage to the high frequency hearing 
than speech frequency after radiotherapy.  Moreover, many studies on hearing 
deterioration after radiotherapy for NPC included patients in more advanced stage and 
had received chemotherapy.  Chemotherapy, especially cisplatin is cytotoxic.  
Chemotherapy will be a confounding variable in many of the studies.  In the current 
cohort, none of the patients had received chemotherapy.  There could be other 
confounding factors affecting hearing in the patients in the five years after 
radiotherapy like diabetes, noise exposure and genetic factors.  We are unable to 
control these factors in contribution to hearing loss and these confounding variables 
may be a factor contributing in the negative findings in the difference in hearing 
between the two groups.  
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 Intensity-modulated radiotherapy offers the radiotherapist the advantage of 
sparing the adjacent organs high dose radiation and should improve the quality of life 
of patients after radiotherapy.  The improvement of quality of life after radiotherapy 
for NPC has been demonstrated in the aspect of preservation of salivary function[1, 5].  
In order to achieve the preservation of salivary function, the contralateral parotid 
gland has been deliberately excluded from the high dose zone during radiotherapy 
planning.  On the other hand, the petrous temporal bone, cochlear and Eustachian tube 
were considered as at risk organs and limited to a maximum of 50Gy radiation.  
Therefore, the cochlear may well receive a radiation dose that will cause damage to 
hearing and this can explain the similar deterioration in hearing between the IMRT 
group and 2DRT group.  Chen et al.[11] demonstrated that radiation dose over 48Gy 
to the cochlear would significantly increased the risk of sensorineural hearing loss; 
though in his study, patients also received ototoxic chemotherapy.  In another cohort 
of patients with head and neck cancer treated with IMRT, Zuur et al. demonstrated a 
that the dose to the coochlear, pretreatment hearing loss, green eyed patients and older 
age all were risk factors for post treatment hearing loss, though the authors did not 
present maximum safe dose for the cochlear for hearing preservation[12].  In our 
current cohort, the patients in the IMRT group would receive a dose of 50Gy to the 
cochlear while the 2DRT group would receive up to 68Gy.  As both groups of 
patients in the current study received more than 48Gy of radiation to the cochlear, this 
can explain the fact that there is no difference in the hearing loss between both groups.   
 Osteoradionecrosis of the external auditory canal and tympanic ring is a 
serious complication of radiotherapy.  The condition affects the quality of life the 
patients.  Osteoradionecrosis was due the endarteritis and subsequent avascular 
necrosis of the bone, first described by Ewing[13].  Ramsden et al.[14] divided 
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temporal bone osteoradionecrosis into the localize form and diffuse form.  Both forms 
of temporal bone ORN would include the tympanic ring, where the blood supply was 
precarious, with the diffuse form involving parts of the temporal bone in addition to 
the tympanic ring.  Osteoradionecrosis is a difficult condition to manage.  Patient 
would present with recurrent otorrhea that require frequent aural toileting and 
treatment of infection.  Osteoradionecrosis of the temporal bone can also lead to 
serious complications including facial nerve palsy and cerebrospinal fluid otorrhea.  
In severe cases, surgical intervention including radical debridement of the necrotic 
bone and flap reconstruction may be required[15].  Moreover, patients with ORN of 
the temporal bone frequently suffer from chronic discharging ears, making the use of 
conventional hearing aids difficult.  Recently there is a report of use of bone-anchored 
hearing aid to circumvent the problem of discharging ears in hearing rehabilitation of 
this group of patients[16]. 
 The present study showed that there is much less incidence of ORN of the 
temporal bone in patients who have received IMRT when comparing to patients who 
have received conventional 2DRT.  In conventional 2DRT, the radiation to the 
nasopharynx is delivered by a lateral opposing field.  The lateral opposing fields will 
include the tympanic ring and petrous temporal bone and both structures would 
receive high dose of radiation.  In IMRT, the radiation is delivered from several 
beams from different angles to the nasopharynx.  The tympanic ring, which is situated 
further away from the nasopharynx and clinical tumor volume (CTV), would receive 
a lesser dose of radiation than conventional 2DRT.  This may explain the observed 
reduction of ORN in patients who received IMRT.  In a similar study, Hsin et al. also 
demonstrated that patients treated with IMRT suffered from less otological 
complications but similar incidence of sensorineural hearing loss[17]. 
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 We cannot find a plausible explanation of increased incidence of otitis 
media with effusion in patients who received IMRT.  The results from Hsin et al. 
study showed similar incidence of otitis media with effusion in patients receiving 
conventional 2DRT or IMRT[17].  Further research will be required to look in to the 
effect of IMRT on the Eustachian tube functions of NPC patients.   
In conclusion, there is significant reduction in the incidence of 
osteoradionecrosis of the external auditory canal in patients who had received IMRT 
but there is no clinical and statistical difference in the long-term bone conduction 
hearing thresholds in nasopharyngeal carcinoma patients who had received IMRT or 
2DRT.  IMRT can reduce the long-term otological complications of nasopharyngeal 
carcinoma patients. 
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